PMID- 21159526
OWN - NLM
STAT- MEDLINE
DCOM- 20110701
LR  - 20221207
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 20
IP  - 3
DP  - 2011 Apr
TI  - Comparison of the retention rates between carbamazepine and valproate as an 
      initial monotherapy in Chinese patients with partial seizures: A ten-year 
      follow-up, observational study.
PG  - 208-13
LID - 10.1016/j.seizure.2010.11.020 [doi]
AB  - PURPOSE: To compare the long-term retention rates of the two most commonly 
      prescribed antiepileptic drugs (AEDs), carbamazepine (CBZ) and valproate (VPA) as 
      an initial monotherapy in Chinese patients with partial seizures. METHODS: This 
      is a retrospective, observational study in a tertiary epilepsy centre. Overall, 
      584 patients were followed during a ten-year period. Kaplan-Meier survival 
      analysis was used to estimate the cumulative probability of retention. Cox 
      proportional hazard model was used to analyze the risk factors for retention 
      rate. RESULTS: The calculated retention rates estimated by Kaplan-Meier survival 
      analysis showed no difference between CBZ and VPA (p=0.074). During the time 
      period from the first six months to two years, the lack of efficacy (LE) that led 
      to drug discontinuation was 10.7% for CBZ compared to 4.5% for VPA (p=0.004). The 
      adverse effects (AEs) that led to discontinuation was 2.4% for CBZ compared to 
      6.3% for VPA (p=0.025). Clinical control that led to discontinuation was 15.9% 
      for CBZ compared to 7.5% for VPA (p=0.001). The five-year remission rate was 
      higher in the CBZ group (33.3%) than in the VPA group (23.2%, p=0.006). Yet in 
      the complex partial seizure subgroup, there was no significant difference between 
      the two drugs (p=0.61). CONCLUSION: Compared with VPA, patients treated with CBZ 
      were more likely to discontinue treatment for LE, and were less likely to 
      discontinue for AEs; however, the two differences above only occurred in the time 
      period between the first six months to two years of treatment. Long-term 
      treatment with CBZ appeared to be more effective in terms of five-year remission 
      and clinical control than VPA.
CI  - Copyright (c) 2010 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Hu, Yida
AU  - Hu Y
AD  - Department of Neurology, The First Affiliated Hospital, Chongqing Medical 
      University, Chongqing 400016, People's Republic of China.
FAU - Huang, Yuanyuan
AU  - Huang Y
FAU - Quan, Fengying
AU  - Quan F
FAU - Hu, Yuming
AU  - Hu Y
FAU - Lu, Yang
AU  - Lu Y
FAU - Wang, Xue-Feng
AU  - Wang XF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20101215
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 33CM23913M (Carbamazepine)
RN  - 614OI1Z5WI (Valproic Acid)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/*therapeutic use
MH  - Asian People
MH  - Carbamazepine/*therapeutic use
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Longitudinal Studies
MH  - Male
MH  - Observation
MH  - Proportional Hazards Models
MH  - *Treatment Outcome
MH  - Valproic Acid/*therapeutic use
MH  - Young Adult
EDAT- 2010/12/17 06:00
MHDA- 2011/07/02 06:00
CRDT- 2010/12/17 06:00
PHST- 2010/09/09 00:00 [received]
PHST- 2010/11/18 00:00 [revised]
PHST- 2010/11/22 00:00 [accepted]
PHST- 2010/12/17 06:00 [entrez]
PHST- 2010/12/17 06:00 [pubmed]
PHST- 2011/07/02 06:00 [medline]
AID - S1059-1311(10)00303-1 [pii]
AID - 10.1016/j.seizure.2010.11.020 [doi]
PST - ppublish
SO  - Seizure. 2011 Apr;20(3):208-13. doi: 10.1016/j.seizure.2010.11.020. Epub 2010 Dec 
      15.